Viemed Healthcare (VMD) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 net revenue of $55 million, a 27% year-over-year increase, surpassing guidance and up 9% sequentially.

• Strong organic growth in core product categories, successful integration of East Alabama HomeMed, and sales force restructuring led to a 15% increase in average monthly ventilator setups per sales rep.

• Ventilator patient count reached a record 10,905, up 4.4% sequentially.

• Employee base expanded to 1,121 as of June 30, 2024.

• Strong cash position of $8.8 million and working capital of $13.5 million as of June 30, 2024.

Financial highlights

• Q2 2024 net revenue was $55 million, up from $43.3 million in Q2 2023 (27% increase).

• Gross margin was 60% and EBITDA margin was 23% for the quarter; gross profit was $32.9 million and Adjusted EBITDA was $12.8 million, a 31% year-over-year increase.

• Net income for Q2 2024 was $1.5 million; EPS (diluted) was $0.04.

• SG&A expenses totaled $26.5 million, up from $20.6 million in Q2 2023.

• Long-term debt at $8.7 million; $50.2 million available under credit facilities.

Outlook and guidance

• Q3 2024 net revenue guidance is $56.5–$57.7 million, with the midpoint representing a 16% year-over-year increase.

• Management expects continued high organic growth rates and strong demand in complex respiratory services.